Publications, Pharmaceutical

Developing a Dry Powder Formulation for Aptar Pharma Prohaler®

Aptar Pharma Prohaler® is a novel, high performance, multidose dry powder inhaler device with a patient-centric design developed to promote patient compliance.

This paper describes the optimization of a model formulation for Prohaler® via manipulation of the concentration of fine lactose and the inclusion of a force control agent, to reduce the strength of interparticle forces and promote dose deaggregation. The relationship between formulation composition and dissolution profile was also investigated. The inclusion of a force control agent was shown to be highly beneficial in promoting aerosolization, resulting in a higher fine particle mass and a finer mass median aerodynamic diameter. This effect was robust with respect to lactose fine concentration which in the absence of a force control agent was also observed to correlate positively with fine particle mass. Consideration of the use of force control agents is highly recommended when developing formulations for Prohaler®.

Download Publication
8 May 2021

Learn more about Prohaler®

Find Out More

This Might Also Be of Interest

24 Apr 2024

Advancing OINDP Clinical Trials with Speed and Efficiency: Strategies for Success

Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Market Insights

Read More
24 Apr 2024

Exploring Nasal Casts in Nasal Drug Development

Publications, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights

Read More
22 Apr 2024

Navigating the Shift to more sustainable Low GWP propellants in pMDIs

Publications, Pharmaceutical, Sustainability, Brand Differentiation, Market Insights, Product Solutions

Read More
26 Mar 2024

Optimizing Preclinical Studies for Intranasal and Pulmonary Programs

Webinars, Pharmaceutical, Market Insights, Product Solutions, Innovation & Insights, Device Innovations

Read More
1 2 3 19
Back To Top